Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

101 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-22

Study Completion Date

2017-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

NCT05638763

Chronic Myeloid Leukemia, Chronic Phase

UNKNOWN PHASE2

Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

NCT04150471

Chronic Myelocytic Leukemia

UNKNOWN

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT01802450

Chronic Myeloid Leukemia

UNKNOWN PHASE2

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

NCT01342679

Chronic Myeloid Leukemia

COMPLETED PHASE2

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

NCT01593254

Chronic Phase Chronic Myeloid Leukemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic myeloid leukemia patients treated with Dasatinib

patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days

Dasatinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dasatinib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women ≥15 years of age
* Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014
* Have received dasatinib as part of their first-line or second-line treatment for at least 45 days

Exclusion Criteria

* Patients who received dasatinib as part of any clinical trial
* Patients who do not have complete data on the data collection sheet
* Patients who do not have medical records available at the moment of the data verification

Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No